A phase I trial of docetaxel and pulse-dose 17-allylamino-17- demethoxygeldanamycin in adult patients with solid tumors

Gopa Iyer,Michael J. Morris,Dana E. Rathkopf,Susan F. Slovin,Macaulay Steers,Steven M. Larson,Lawrence H. Schwartz,Tracy Curley,Anthony Delacruz,Qing Ye,Glenn Heller,Merrill J. Egorin,S. Percy Ivy,Neal Rosen,Howard I. Scher,David B. Solit

A phase I trial of docetaxel and pulse-dose 17-allylamino-17- demethoxygeldanamycin in adult patients with solid tumors

2012

Gopa Iyer
Michael J. Morris
Dana E. Rathkopf
Susan F. Slovin
Macaulay Steers
Steven M. Larson
Lawrence H. Schwartz
Tracy Curley
Anthony Delacruz
Qing Ye
Glenn Heller
Merrill J. Egorin
S. Percy Ivy
Neal Rosen
Howard I. Scher
David B. Solit

Purpose To define maximum tolerated dose (MTD), clinical toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered in combination with docetaxel once every 21 days in patients with advanced solid tumor malignancies.

Keywords:

Geldanamycin
Advanced Solid Tumor
HSP90 Heat-Shock Proteins
Pharmacology
Maximum tolerated dose
Pulse (signal processing)
Pharmacokinetics
Docetaxel
Medicine
17-Allylamino-17-demethoxygeldanamycin
adult patients
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations